Illimis Therapeutics specializes in developing novel biologics based on its proprietary chimeric fusion protein platform. The platform aims to address neurodegenerative diseases such as Alzheimer's by utilizing TAM receptor-mediated phagocytosis, which reduces neuroinflammation
